Primary Sjögren’s Disease ACR China Phase 3 Data Update Oct 28, 2025 4:30 PM EDT Click Here for Webcast Supporting Materials Slide Presentation: 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s Disease 3.3 MB Poster Presentation: Efficacy and safety of telitacicept in participants with Sjögren’s disease: Results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study 551 KB
Slide Presentation: 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s Disease 3.3 MB
Poster Presentation: Efficacy and safety of telitacicept in participants with Sjögren’s disease: Results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study 551 KB